PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28972595-0	2018	Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.	ibrutinib	0-9	CD274 molecule	Homo sapiens	155-160	
28123879-5	2016	Meanwhile, ibrutinib drove Th1-selective pressure in T lymphocytes, thus, reducing the PD-1 and PDL-1 expression.	ibrutinib	11-20	CD274 molecule	Homo sapiens	96-101	
30209121-9	2018	We also found that BCR pathway inhibition by BTK inhibitors (ibrutinib, acalabrutinib, and BGB-3111) blocks NFATc1 and STAT3 activation, thereby inhibiting IL-10 and PD-L1 expression.	ibrutinib	61-70	CD274 molecule	Homo sapiens	166-171	
32532074-9	2020	Ibrutinib exerts multiple antineoplastic effects, such as on-target BTK inhibition, off-target kinase inhibition, and immunomodulation by interference with myeloid-derived suppressor cells (MDSCs), programmed death-ligand 1 (PD-L1), and T cell response.	ibrutinib	0-9	CD274 molecule	Homo sapiens	198-223	
32532074-9	2020	Ibrutinib exerts multiple antineoplastic effects, such as on-target BTK inhibition, off-target kinase inhibition, and immunomodulation by interference with myeloid-derived suppressor cells (MDSCs), programmed death-ligand 1 (PD-L1), and T cell response.	ibrutinib	0-9	CD274 molecule	Homo sapiens	225-230	
28972595-5	2018	In peripheral blood samples collected prospectively from CLL patients treated with ibrutinib monotherapy, we observed selective and durable downregulation of PD-L1 on CLL cells by 3 months post-treatment.	ibrutinib	83-92	CD274 molecule	Homo sapiens	158-163	
28641100-7	2017	Furthermore, based on its molecular activity and safety, ibrutinib has been considered as a partner for treatment combination with PI3K/AKT/mTOR inhibitors or with immune-checkpoint inhibitors, inhibiting immunosuppressive signals from the tumor microenvironment, and overcoming the immune resistance to current anti-PD1/PDL1 immunotherapeutic drugs by the CXCR4/CXCL2 pathway regulation.	ibrutinib	57-66	CD274 molecule	Homo sapiens	321-325